Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
lululemon athletica inc.
LULU·Consumer Discretionary
D ★Strong Sell
Current$98.97
Sep 14, 2026

lululemon's premium brand, cash generation and depressed valuation offer turnaround upside, but double-digit Americas comp declines and falling earnings estimates make value-trap risk too high until momentum stabilizes.

Score
59
Corteva, Inc.
CTVA·Materials
C ★★Sell
Current$9.43
Nov 14, 2026

Corteva retains valuable crop protection technology and recovery potential after its separation, but Brazil's prolonged downturn, weakened earnings guidance and uncertain standalone cash generation threaten near-term shareholder returns.

Score
58
Rocket Lab Corporation
RKLB·Industrials
C ★★Sell
Current$66.15
Nov 12, 2026

Rocket Lab's expanding space systems franchise, record backlog, and Neutron opportunity offer exceptional long-term growth potential, but demanding valuation, cash burn, and acquisition-related dilution undermine current risk-adjusted returns.

Score
58
Liberty Live Holdings, Inc.
LLYVK·Communication Services
C ★★Sell
Current$106.75
Nov 10, 2026

Liberty Live offers concentrated exposure to Live Nation and growing premium event hospitality demand, but negative operating cash flow, financing complexity, and regulatory exposure constrain the investment case.

Score
58
DraftKings Inc.
DKNG·Consumer Discretionary
C ★★Sell
Current$18.51
Nov 8, 2026

DraftKings could benefit from long-term growth in online gaming and prediction markets, but deteriorating cash conversion and heavy promotional investment threaten the profitability needed to justify sustained shareholder returns.

Score
58
Acadia Healthcare Company, Inc.
ACHC·Healthcare
C ★★Sell
Current$37.00
Nov 7, 2026

Acadia could benefit from growing behavioral healthcare demand and improving hospital cash flows, but unresolved regulatory investigations, elevated leverage, and uneven profitability undermine its risk-adjusted investment appeal.

Score
58
Revolution Medicines, Inc.
RVMD·Healthcare
C ★★Sell
Current$192.28
Nov 7, 2026

Revolution Medicines has a differentiated RAS-targeted oncology franchise with major expansion potential, but its demanding valuation, negative cash flow and shareholder dilution limit the investment appeal.

Score
58
Ashland Inc.
ASH·Materials
C ★★Sell
Current$76.28
Nov 6, 2026

Ashland's specialized pharmaceutical and personal-care ingredients offer a credible earnings-recovery opportunity, but weak capital returns, persistent manufacturing inefficiencies, and a demanding valuation limit near-term investment appeal.

Score
58
ReNew Energy Global Plc
RNW·Utilities
C ★★Sell
Current$6.93
Nov 5, 2026

ReNew offers exposure to India's expanding renewable electricity market through a large contracted generation portfolio, but heavy leverage and a pending $7.02-per-share take-private transaction constrain the remaining public-equity opportunity.

Score
58
FedEx Freight Holding Company, Inc.
FDXF·Industrials
C ★★Sell
Current$126.04
Nov 1, 2026

FedEx Freight's leading North American LTL network offers long-term margin recovery potential, but demanding valuation, cyclical freight weakness, and substantial post-spin leverage constrain its near-term investment appeal.

Score
58
Hyatt Hotels Corporation
H·Consumer Discretionary
C ★★Sell
Current$180.57
Nov 1, 2026

Hyatt's premium hotel brands and growing asset-light fee platform offer attractive long-term cash-flow potential, but a demanding valuation and substantial leverage limit the margin of safety.

Score
58
OGE Energy Corp.
OGE·Utilities
C ★★Sell
Current$49.47
Nov 1, 2026

OGE Energy offers durable regulated electricity revenue, a stable dividend, and infrastructure-led growth opportunities, but elevated valuation, heavy capital spending, and potential dilution constrain shareholder returns.

Score
58